Biogen (NASDAQ:BIIB) picked up a strong endorsement from Wall Street on Wednesday, as UBS analyst Michael Yee upgraded the ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Biogen for a ...

Biogen Inc. (NASDAQ:BIIB) is one of the best stem cell therapy stocks to buy. On April 22, Biogen Inc. (NASDAQ:BIIB) was ...

Biogen has agreed to acquire ​Apellis ​Pharmaceuticals ​for about $5.6 billion in cash, expanding its portfolio ⁠of ‌rare-disease medicines.

The manufacturing of the drug will be retained by TJ Biopharma at its site in Hangzhou, which would make felzartamab China’s ...

Biogen Inc (NASDAQ:BIIB, XETRA:IDP) has been upgraded to ‘Buy’ from ‘Neutral’ by UBS analysts, who also raised their price ...

April 20 (Reuters) - Biogen said on Monday it had agreed to pay up to $850 million to acquire exclusive rights in Greater ...

Biogen (NASDAQ:BIIB | BIIB Price Prediction) stock just earned a strong endorsement from Wells Fargo on Monday, as analyst ...

Biogen (BIIB) has reached a deal worth up to $850M with TJ Bio to acquire exclusive rights in Greater China for felzartamab, an antibody therapy designed to target various immune-mediated disorders, ...

One of the healthier stocks on the market Friday was veteran biotech Biogen (NASDAQ: BIIB). The company unveiled its final set of fundamentals for 2025, and it crushed analyst estimates for both ...

Biogen has agreed to pay up to $850 million to acquire TJ Bio's exclusive rights to felzartamab in the Greater China region, giving it worldwide rights to the investigational drug that is currently in ...

AI-generated summary reviewed by our newsroom. Read our AI Policy. Biogen plans to beef up its Research Triangle Park operations with $2 billion in new local spending, the company announced Monday.